Brain Tumor Drug Market Report: Trends, Forecast and Competitive Analysis to 2030

Brain Tumor Drug Trends and Forecast

The future of the global brain tumor drug market looks promising with opportunities in the hospital pharmacy and retail & online pharmacy markets. The global brain tumor drug market is expected to grow with a CAGR of 8.7% from 2024 to 2030. The major drivers for this market are rising prevalence of smoking, increasing aging population, and stress and exposure to electromagnetic radiation.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Brain Tumor Drug by Segment

The study includes a forecast for the global brain tumor drug by therapy, indication, distribution channel, and region.

Brain Tumor Drug Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:

• Targeted Therapy
• Chemotherapy
• Immunotherapy
• Others

Brain Tumor Drug Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

• Pituitary
• Meningioma
• Glioma
• Others

Brain Tumor Drug Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacy
• Retail & Online Pharmacy

Brain Tumor Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Brain Tumor Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies brain tumor drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the brain tumor drug companies profiled in this report include-

• Hoffmann-La Roche
• Pfizer
• Novartis
• Amgen
• Merck & Co

Brain Tumor Drug Market Insights

Lucintel forecasts that chemotherapy will remain the largest segment over the forecast period as it is adjuvant therapy, which is employed for the treatment of brain tumors.

Within this market, hospital pharmacy will remain larger segment as drugs designed to treat the condition are prescribed and necessitate administration within hospital settings.

North America will remain the largest region over the forecast period due to favorable reimbursement policies and rising launch of new drugs in the market.

Features of the Global Brain Tumor Drug Market

Market Size Estimates: Brain tumor drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Brain tumor drug market size by therapy, indication, distribution channel, and region in terms of value ($B).

Regional Analysis: Brain tumor drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapy, indication, distribution channels, and regions for the brain tumor drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the brain tumor drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for brain tumor drug market?

Answer: The global brain tumor drug market is expected to grow with a CAGR of 8.7% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the brain tumor drug market?

Answer: The major drivers for this market are rising prevalence of smoking, increasing aging population and stress and exposure to electromagnetic radiation.

Q3. What are the major segments for brain tumor drug market?

Answer: The future of the brain tumor drug market looks promising with opportunities in the hospital pharmacy and retail & online pharmacy markets.

Q4. Who are the key brain tumor drug market companies?

Answer: Some of the key brain tumor drug companies are as follows:

• Hoffmann-La Roche
• Pfizer
• Novartis
• Amgen
• Merck & Co

Q5. Which brain tumor drug market segment will be the largest in future?

Answer: Lucintel forecasts that chemotherapy will remain the largest segment over the forecast period as it is adjuvant therapy, which is employed for the treatment of brain tumors.

Q6. In brain tumor drug market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to favorable reimbursement policies and rising launch of new drugs in the market.

Q.7 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the brain tumor drug market by therapy (targeted therapy, chemotherapy, immunotherapy, and others), indication (pituitary, meningioma, glioma, and others), distribution channel (hospital pharmacy and retail & online pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?